-
1دورية أكاديمية
المؤلفون: V. B. Vasilyuk, A. Yu. Boroduleva, P. D. Sobolev, A. G. Nikiforova, V. G. Mozgovaya, O. V. Filon, A. V. Zinkovskaya, V. G. Ignatiev, M. Yu. Samsonov, I. S. Kozlova, E. K. Khanonina
المصدر: Фармация и фармакология (Пятигорск), Vol 10, Iss 6, Pp 562-572 (2023)
مصطلحات موضوعية: covid-19, молнупиравир, биоэквивалентность, фармакокинетика, n-гидроксицитидин, Therapeutics. Pharmacology, RM1-950
وصف الملف: electronic resource
العلاقة: https://www.pharmpharm.ru/jour/article/view/1221Test; https://doaj.org/toc/2307-9266Test; https://doaj.org/toc/2413-2241Test
-
2دورية أكاديمية
المؤلفون: R. A. Oseshnyuk, A. G. Nikiforova, A. Yu. Boroduleva, P. D. Sobolev, S. A. Lesnichuk, B. B. Garyaev, A. A. Abramova, V. G. Mozgovaya, O. V. Filon, A. V. Zinkovskaya, A. N. Dolgorukova, E. K. Khanonina, V. G. Ignatiev, M. Yu. Samsonov, Р. А. Осешнюк, А. Г. Никифорова, А. Ю. Бородулева, П. Д. Соболев, С. А. Лесничук, Б. Б. Гаряев, А. А. Абрамова, В. Г. Мозговая, О. В. Филон, А. В. Зинковская, А. Н. Долгорукова, Е. К. Ханонина, В. Г. Игнатьев, М. Ю. Самсонов
المساهمون: The work was carried out with the financing of the R-Pharm group., Работа выполнялась при финансировании группы компаний АО «Р-Фарм».
المصدر: Pharmacy & Pharmacology; Том 11, № 1 (2023); 62-71 ; Фармация и фармакология; Том 11, № 1 (2023); 62-71 ; 2413-2241 ; 2307-9266 ; undefined
مصطلحات موضوعية: воспроизведенный препарат, bioequivalence, pharmacokinetics, nirmatrelvir, ritonavir, generic drug, биоэквивалентность, фармакокинетика, нирматрелвир, ритонавир
وصف الملف: application/pdf
العلاقة: https://www.pharmpharm.ru/jour/article/view/1259/951Test; https://www.pharmpharm.ru/jour/article/view/1259/952Test; Joyce R.P., Hu V.W., Wang J. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations // Med. Chem. Res. – 2022. – Vol. 31, No. 10. – P. 1637–1646. DOI:10.1007/s00044-022-02951-6; Vangeel L., Chiu W., De Jonghe S., Maes P., Slechten B., Raymenants J., André E., Leyssen P., Neyts J., Jochmans D. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern // Antiviral. Res. – 2022. – Vol. 198. – Art. ID: 105252. DOI:10.1016/j.antiviral.2022.105252; Marzi M., Vakil M.K., Bahmanyar M., Zarenezhad E. Paxlovid: Mechanism of Action, Synthesis, and In Silico Study // Biomed. Res. Int. – 2022. – Vol. 2022. – Art. ID: 7341493. DOI:10.1155/2022/7341493; Singh R.S.P., Toussi S.S., Hackman F., Chan P.L., Rao R., Allen R., Van Eyck L., Pawlak S., Kadar E.P., Clark F., Shi H., Anderson A.S., Binks M., Menon S., Nucci G., Bergman A. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir // Clin. Pharmacol. Ther. – 2022. – Vol. 112, No. 1. – P. 101–111. DOI:10.1002/cpt.2603; Catlin N.R., Bowman C.J., Campion S.N., Cheung J.R., Nowland W.S., Sathish J.G., Stethem C.M., Updyke L., Cappon G.D. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models // Reprod. Toxicol. – 2022. – Vol. 108. – P. 56–61. DOI:10.1016/j.reprotox.2022.01.006; Jeong J.H., Chokkakula S., Min S.C., Kim B.K., Choi W.S., Oh S., Yun Y.S., Kang D.H., Lee O.J., Kim E.G., Choi J.H., Lee J.Y., Choi Y.K., Baek Y.H., Song M.S. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice // Antiviral. Res. – 2022. – Vol. 208. – Art. ID: 105430. DOI:10.1016/j.antiviral.2022.105430; Greasley S.E., Noell S., Plotnikova O., Ferre R., Liu W., Bolanos B., Fennell K., Nicki J., Craig T., Zhu Y., Stewart A.E., Steppan C.M. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants // J. Biol. Chem. – 2022. – Vol. 298, No. 6. – Art. ID: 101972. DOI:10.1016/j.jbc.2022.101972; Owen D.R., Allerton C.M.N., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., Boras B., Cardin R.D., Carlo A., Coffman K.J., Dantonio A., Di L., Eng H., Ferre R., Gajiwala K.S., Gibson S.A., Greasley S.E., Hurst B.L., Kadar E.P., Kalgutkar A.S., Lee J.C., Lee J., Liu W., Mason S.W., Noell S., Novak J.J., Obach R.S., Ogilvie K., Patel N.C., Pettersson M., Rai D.K., Reese M.R., Sammons M.F., Sathish J.G., Singh R.S.P., Steppan C.M., Stewart A.E., Tuttle J.B., Updyke L., Verhoest P.R., Wei L., Yang Q., Zhu Y. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 // Science. – 2021. – Vol. 374, No. 6575. – P. 1586–1593. DOI:10.1126/science.abl4784; Wen W., Chen C., Tang J., Wang C., Zhou M., Cheng Y., Zhou X., Wu Q., Zhang X., Feng Z., Wang M., Mao Q. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis // Ann. Med. – 2022. – Vol. 54, No. 1. – P. 516–523. DOI:10.1080/07853890.2022.2034936; Drożdżal S., Rosik J., Lechowicz K., Machaj F., Szostak B., Przybyciński J., Lorzadeh S., Kotfis K., Ghavami S., Łos M.J. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment // Drug Resist. Updat. – 2021. – Vol. 59. – Art. ID: 100794. DOI:10.1016/j.drup.2021.100794; Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Simón-Campos A., Pypstra R., Rusnak J.M.; EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 // N. Engl. J. Med. – 2022. – Vol. 386, No. 15. – P. 1397–1408. DOI:10.1056/NEJMoa2118542; Wong C.K.H., Au I.C.H., Lau K.T.K., Lau E.H.Y., Cowling B.J., Leung G.M. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study // Lancet. – 2022. – Vol. 400, No. 10359. – P. 1213–1222. DOI:10.1016/S0140-6736(22)01586-0; Wong C.K.H., Au I.C.H., Lau K.T.K., Lau E.H.Y., Cowling B.J., Leung G.M. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study // Lancet Infect. Dis. – 2022. – Vol. 22, No. 12. – P. 1681–1693. DOI:10.1016/S1473-3099, No. 22)00507-2; Najjar-Debbiny R., Gronich N., Weber G., Khoury J., Amar M., Stein N., Goldstein L.H., Saliba W. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients // Clin. Infect. Dis. – 2023. – Vol. 76, No. 3. – P. 342–349. DOI:10.1093/cid/ciac443. Erratum in: Clin Infect Dis. – 2023. – Vol. 76, No. 6. – P. 1158–1159.; Dryden-Peterson S., Kim A., Kim A.Y., Caniglia E.C., Lennes I.T., Patel R., Gainer L., Dutton L., Donahue E., Gandhi R.T., Baden L.R., Woolley A.E. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System: A Population-Based Cohort Study // Ann. Intern. Med. – 2023. – Vol. 176, No. 1. – P. 77–84. DOI:10.7326/M22-2141; Yuan Y., Jiao B., Qu L., Yang D., Liu R. The development of COVID-19 treatment // Front. Immunol. – 2023. – Vol. 14. – Art. ID: 1125246. DOI:10.3389/fimmu.2023.1125246; Zhang J.J., Dong X., Liu G.H., Gao Y.D. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality // Clin. Rev. Allergy Immunol. – 2023. – Vol. 64, No. 1. – P. 90–107. DOI:10.1007/s12016-022-08921-5; Lipsitch M., Krammer F., Regev-Yochay G., Lustig Y., Balicer R.D. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact // Nat. Rev. Immunol. – 2022. – Vol. 22, No. 1. – P. 57–65. DOI:10.1038/s41577-021-00662-4; Reis S., Metzendorf M.I., Kuehn R., Popp M., Gagyor I., Kranke P., Meybohm P., Skoetz N., Weibel S. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19 // Cochrane Database Syst. Rev. – 2022. – Vol. 9, No. 9. – Art. ID: CD015395. DOI:10.1002/14651858.CD015395.pub2; Große-Michaelis I., Proestel S., Rao R.M., Dillman B.S., Bader-Weder S., Macdonald L., Gregory W. MedDRA Labeling Groupings to Improve Safety Communication in Product Labels // Ther. Innov. Regul. Sci. – 2023. – Vol. 57, No. 1. – P. 1–6. DOI:10.1007/s43441-022-00393-1; Ullrich S., Nitsche C. The SARS-CoV-2 main protease as drug target // Bioorg. Med. Chem. Lett. – 2020. – Vol. 30, No. 17. – Art. ID: 127377. DOI:10.1016/j.bmcl.2020.127377; Eng H., Dantonio A.L., Kadar E.P., Obach R.S., Di L., Lin J., Patel N.C., Boras B., Walker G.S., Novak J.J., Kimoto E., Singh R.S.P., Kalgutkar A.S. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans // Drug Metab. Dispos. – 2022. – Vol. 50, No. 5. – P. 576–590. DOI:10.1124/dmd.121.000801; Loos N.H.C., Beijnen J.H., Schinkel A.H. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism? // Int. J. Mol. Sci. – 2022. – Vol. 23, No. 17. – Art. ID: 9866. DOI:10.3390/ijms23179866; https://www.pharmpharm.ru/jour/article/view/1259Test
الإتاحة: https://doi.org/10.19163/2307-9266-2023-11-1-62-71Test
https://doi.org/10.1007/s00044-022-02951-6Test
https://doi.org/10.1016/j.antiviral.2022.105252Test
https://doi.org/10.1155/2022/7341493Test
https://doi.org/10.1002/cpt.2603Test
https://doi.org/10.1016/j.reprotox.2022.01.006Test
https://doi.org/10.1016/j.antiviral.2022.105430Test
https://doi.org/10.1016/j.jbc.2022.101972Test
https://doi.org/10.1126/science.abl4784Test
https://doi.org/10.1080/07853890.2022.2034936Test -
3
المؤلفون: Hui Li, Sergei A. Eremin, Peiwu Li, Anna Yu Boroduleva, Yang Qingqing, Qi Zhang, Jing Wu
المصدر: Analytical Methods. 9:6814-6822
مصطلحات موضوعية: Detection limit, Analyte, Chromatography, Chemistry, General Chemical Engineering, 010401 analytical chemistry, General Engineering, 02 engineering and technology, Assay sensitivity, 021001 nanoscience & nanotechnology, Mass spectrometry, 01 natural sciences, 0104 chemical sciences, Analytical Chemistry, chemistry.chemical_compound, Reagent, Carbaryl, Sample preparation, 0210 nano-technology, Fluorescence anisotropy
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::c1a83ac6de7a301287e50c8e0c536839Test
https://doi.org/10.1039/c7ay02091kTest -
4
المؤلفون: Sergei A. Eremin, A. Yu. Boroduleva
المصدر: Journal of Analytical Chemistry. 71:949-954
مصطلحات موضوعية: Detection limit, 2,4-Dichlorophenoxyacetic acid, Chromatography, 010401 analytical chemistry, Relative standard deviation, 010501 environmental sciences, 01 natural sciences, Fluorescence, 0104 chemical sciences, Analytical Chemistry, chemistry.chemical_compound, chemistry, TRACER, Fluorescence polarization immunoassay, Fluorescein, 0105 earth and related environmental sciences
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::dfc5d3c92865be352ecb616ef0ec4fdbTest
https://doi.org/10.1134/s1061934816090045Test -
5
المؤلفون: Ming Ma, Hongjie You, Xiude Hua, Minghua Wang, Lu Feng, Sergei A. Eremin, Anna Yu Boroduleva, Mo Chen, Rui Yang
المصدر: Food Analytical Methods. 9:2471-2478
مصطلحات موضوعية: Detection limit, Chromatography, Chemistry, 010401 analytical chemistry, 02 engineering and technology, 021001 nanoscience & nanotechnology, 01 natural sciences, Applied Microbiology and Biotechnology, High-performance liquid chromatography, 0104 chemical sciences, Analytical Chemistry, Homogeneous, Fluorescence polarization immunoassay, 0210 nano-technology, Safety, Risk, Reliability and Quality, Safety Research, Imidaclothiz, Food Science
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::3f753341afd151813720d528a33cafe4Test
https://doi.org/10.1007/s12161-016-0434-5Test -
6
المؤلفون: Sergei A. Eremin, Guonian Zhu, Ying Liu, Anna Yu Boroduleva, Rui Liu, Yirong Guo
المصدر: Analytical Methods. 8:6636-6644
مصطلحات موضوعية: Detection limit, Residue (complex analysis), Chromatography, medicine.diagnostic_test, Chemistry, General Chemical Engineering, 010401 analytical chemistry, General Engineering, 010501 environmental sciences, 01 natural sciences, Fluorescence, Rapid detection, 0104 chemical sciences, Analytical Chemistry, Immunoassay, Fluorescence polarization immunoassay, medicine, Brown rice, Gas chromatography, 0105 earth and related environmental sciences
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::92dfda5ea8503232d3197a3da35f4cd0Test
https://doi.org/10.1039/c6ay00908eTest -
7
المؤلفون: Juan J. Manclús, Angel Montoya, Sergei A. Eremin, Anna Yu Boroduleva
المصدر: RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
instnameمصطلحات موضوعية: 02 engineering and technology, Chlorobenzenes, 01 natural sciences, Biochemistry, Fluorescence polarization immunoassay, Analytical Chemistry, TECNOLOGIA ELECTRONICA, Simple sample, Limit of Detection, Tandem Mass Spectrometry, Thiabendazole, Tetraconazole, Pesticides, Chromatography, High Pressure Liquid, Triticum, Fungicides, Detection limit, Anthelmintics, Chromatography, Chemistry, 010401 analytical chemistry, Reproducibility of Results, Pesticide, Triazoles, 021001 nanoscience & nanotechnology, 0104 chemical sciences, Fungicides, Industrial, Wheat, Indicators and Reagents, 0210 nano-technology
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae454a1adeade292367cd44e94a6e64bTest
https://doi.org/10.1007/s00216-018-1296-zTest